Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Taysha Gene Therapies (NASDAQ:TSHA) had its price objective increased by Canaccord Genuity Group from $6.00 to $8.00 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would indicate a potential upside of 288.35% from the company’s previous close.

A number of other equities analysts have also recently weighed in on TSHA. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Trading Down 9.3 %

Shares of TSHA stock opened at $2.06 on Friday. Taysha Gene Therapies has a 1-year low of $1.19 and a 1-year high of $4.32. The firm has a market cap of $422.18 million, a PE ratio of 3.27 and a beta of 0.44. The company has a 50-day moving average of $1.98 and a two-hundred day moving average of $2.38. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.22.

Institutional Investors Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Creative Planning purchased a new position in shares of Taysha Gene Therapies during the third quarter worth about $28,000. China Universal Asset Management Co. Ltd. grew its stake in Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after buying an additional 17,446 shares during the last quarter. Privium Fund Management B.V. boosted its holdings in shares of Taysha Gene Therapies by 21.8% in the third quarter. Privium Fund Management B.V. now owns 120,000 shares of the company’s stock valued at $241,000 after acquiring an additional 21,500 shares during the period. Principal Financial Group Inc. purchased a new stake in Taysha Gene Therapies in the 2nd quarter valued at $48,000. Finally, Artal Group S.A. boosted its stake in Taysha Gene Therapies by 0.7% during the 1st quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock worth $10,583,000 after purchasing an additional 24,444 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.